- Home
- IZM vs BCAB Comparison
IZM vs BCAB Comparison
Compare IZM & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IZM
- BCAB
- Stock Information
- Founded
- IZM 2011
- BCAB 2007
- Country
- IZM China
- BCAB United States
- Employees
- IZM N/A
- BCAB N/A
- Industry
- IZM Consumer Electronics/Video Chains
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- IZM Consumer Discretionary
- BCAB Health Care
- Exchange
- IZM Nasdaq
- BCAB Nasdaq
- Market Cap
- IZM 21.1M
- BCAB 22.3M
- IPO Year
- IZM 2023
- BCAB 2020
- Fundamental
- Price
- IZM $2.39
- BCAB $0.48
- Analyst Decision
- IZM
- BCAB Buy
- Analyst Count
- IZM 0
- BCAB 2
- Target Price
- IZM N/A
- BCAB $1.00
- AVG Volume (30 Days)
- IZM 28.8K
- BCAB 505.1K
- Earning Date
- IZM 07-25-2025
- BCAB 05-06-2025
- Dividend Yield
- IZM N/A
- BCAB N/A
- EPS Growth
- IZM N/A
- BCAB N/A
- EPS
- IZM N/A
- BCAB N/A
- Revenue
- IZM $177,933,890.00
- BCAB $11,000,000.00
- Revenue This Year
- IZM N/A
- BCAB N/A
- Revenue Next Year
- IZM N/A
- BCAB N/A
- P/E Ratio
- IZM N/A
- BCAB N/A
- Revenue Growth
- IZM N/A
- BCAB N/A
- 52 Week Low
- IZM $1.18
- BCAB $0.24
- 52 Week High
- IZM $3.19
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- IZM 58.47
- BCAB 57.81
- Support Level
- IZM $2.28
- BCAB $0.44
- Resistance Level
- IZM $2.42
- BCAB $0.56
- Average True Range (ATR)
- IZM 0.11
- BCAB 0.05
- MACD
- IZM -0.03
- BCAB 0.01
- Stochastic Oscillator
- IZM 45.45
- BCAB 61.17
About IZM ICZOOM Group Inc.
ICZOOM Group Inc is engaged in the sale of electronic component products to customers in China. These products are used by small and medium-sized enterprises (SMEs) in the consumer electronic industry, Internet of Things (IoT), automotive electronics, and industrial control segment. In addition to the sales of electronic component products, also provides services to customers such as temporary warehousing, logistic and shipping, and customs clearance and charges them additional service commission fees. The company earns maximum revenue from sale of electronic components.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.